COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine

[1]  A. Vita,et al.  The impact of the Covid-19 pandemic on patients with schizophrenia , 2021, European Neuropsychopharmacology.

[2]  L. Dratcu,et al.  Clozapine in the Time of COVID-19 , 2020, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[3]  J. MacCabe,et al.  Clozapine treatment and risk of COVID-19 infection: retrospective cohort study , 2020, The British Journal of Psychiatry.

[4]  S. Tavangar,et al.  Pathologic features of COVID-19: A concise review , 2020, Pathology - Research and Practice.

[5]  W. Honer,et al.  Consensus statement on the use of clozapine during the COVID-19 pandemic , 2020, Journal of psychiatry & neuroscience : JPN.

[6]  David Taylor,et al.  Clozapine prescribing in COVID-19 positive medical inpatients: a case series , 2020, Therapeutic advances in psychopharmacology.

[7]  E. Sanz,et al.  Data From the World Health Organization's Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions. , 2019, Schizophrenia bulletin.

[8]  C. Correll,et al.  Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years , 2019, Schizophrenia bulletin.

[9]  J. MacCabe,et al.  Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine , 2019, Journal of psychopharmacology.

[10]  J. MacCabe,et al.  Clozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study , 2018, Acta psychiatrica Scandinavica.

[11]  M. Owen,et al.  Premature mortality among people with severe mental illness — New evidence from linked primary care data , 2018, Schizophrenia Research.

[12]  Chia-Hung Chen,et al.  Risk of pleural empyema in patients with schizophrenia: a nationwide propensity-matched cohort study in Taiwan , 2018, BMJ Open.

[13]  K. Walters,et al.  Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014 , 2017, The British journal of psychiatry : the journal of mental science.

[14]  C. Gasse,et al.  Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. , 2017, The American journal of psychiatry.

[15]  E. Susser,et al.  Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas , 2017, World psychiatry : official journal of the World Psychiatric Association.

[16]  D. Siskind,et al.  Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis , 2016, British Journal of Psychiatry.

[17]  Andrea C. Fernandes,et al.  Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource , 2016, BMJ Open.

[18]  Matthew Broadbent,et al.  The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders , 2014, Schizophrenia bulletin.

[19]  P. Haddad.  Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia , 2013, Evidence-Based Mental Health.

[20]  C. Kuo,et al.  Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. , 2013, Schizophrenia bulletin.

[21]  F. Chou,et al.  The incidence and all-cause mortality of pneumonia in patients with schizophrenia: a nine-year follow-up study. , 2013, Journal of psychiatric research.

[22]  M. Goldacre,et al.  Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies , 2012, Thorax.

[23]  Graham Thornicroft,et al.  The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data , 2009, BMC psychiatry.

[24]  P. Weiden,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[25]  J. Rasimas,et al.  Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months , 2017, International clinical psychopharmacology.

[26]  James M. Stone,et al.  Therapeutic Advances in Psychopharmacology , 2014 .

[27]  J. Newcomer.  Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.